Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?
This trial is active, not recruiting.
|Conditions||anemia, cervix neoplasms|
|Treatment||nesp - novel erythropoiesis stimulating protein|
|Sponsor||Mirhashemi, Ramin, M.D.|
|Start date||September 2001|
|End date||March 2003|
|Trial size||64 participants|
|Trial identifier||NCT00039884, 01/155A|
This is a clinical trial (a type of research study) designed to describe the efficacy (effectiveness) and toxicity (safety) of a new medical treatment, NESP (Novel Erythropoiesis Stimulating Protein). This study will be offered to patients with cervical cancer undergoing a combination of chemotherapy and radiation. This treatment may lower your red blood cells. The use of NESP may stimulate the body to produce more red blood cells. Our hypothesis is that higher red blood cells will be beneficial to the patient during treatment for cervical cancer.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Female participants at least 18 years old.
- Consent form completed and signed - Hemoglobin between 9-13 g/dL - Life expectancy of at least 4 months - Karnofsky Performance Status =/> 70 - No evidence of hemolysis, GI bleeding, or bleeding due to recent surgery - Adequate renal and liver function
|Official title||Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.|
Call for more information